Adma Biologics (ADMA) Capital Leases (2011 - 2021)
Adma Biologics' (ADMA) quarterly Capital Leases came in at $6.4 million in Q1 2021, up 250.48% YoY from $1.8 million in Q1 2020, and up 48.12% on a QoQ basis from $4.3 million in Q4 2020.
Adma Biologics (ADMA) Capital Leases (2011 - 2021) Analysis & Trends
Adma Biologics (ADMA) has 10 years of Capital Leases data on file, last reported at $6.4 million in Q1 2021.
- Quarterly Capital Leases rose 250.48% year-over-year to $6.4 million in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $6.4 million (up 250.48% YoY) and the FY2020 annual result came in at $4.3 million, up 232.79% from the prior year.
- Capital Leases grew to $6.4 million in Q1 2021, from $4.3 million in the prior quarter.
- In the past five years, Capital Leases ranged from a high of $6.4 million in Q1 2021 to a low of $15319.0 in Q1 2017.
- A 5-year average of $1.8 million and a median of $1.4 million in 2019 frame the typical range for Capital Leases.
- Annual changes were most pronounced in 2019 — Capital Leases soared 993.69% — and 2020, when it gained 25.33%.
- Tracing ADMA's Capital Leases over 5 years: stood at $15319.0 in 2017, then soared by 677.34% to $119080.0 in 2018, then soared by 993.69% to $1.3 million in 2019, then soared by 232.79% to $4.3 million in 2020, then soared by 48.12% to $6.4 million in 2021.
- The last three Capital Leases figures came in at $6.4 million (Q1 2021), $4.3 million (Q4 2020), and $2.9 million (Q3 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 6.42 Mn |
| Dec 31, 2020 | 4.33 Mn |
| Sep 30, 2020 | 2.86 Mn |
| Mar 31, 2020 | 1.83 Mn |
| Dec 31, 2019 | 1.30 Mn |
| Sep 30, 2019 | 1.36 Mn |
| Jun 30, 2019 | 1.41 Mn |
| Mar 31, 2019 | 1.46 Mn |
| Dec 31, 2018 | 119,080.00 |
| Sep 30, 2018 | 126,765.00 |
| Jun 30, 2018 | 134,323.00 |
| Mar 31, 2017 | 15,319.00 |
| Dec 31, 2016 | 19,697.00 |
| Dec 31, 2015 | 36,256.00 |
| Mar 31, 2013 | 74,832.00 |
| Dec 31, 2012 | 77,890.00 |
| Sep 30, 2012 | 81,111.00 |
| Jun 30, 2012 | 83,804.00 |
| Mar 31, 2012 | 86,663.00 |
| Dec 31, 2011 | 88,613.00 |